Vitamin D insufficiency (circulating 25(OH)D levels <30 ng/dL) is endemic in the human population with more than a billion people affected worldwide. 1 Epidemiological data indicate that vitamin D deficiency (circulating 25(OH)D levels <20 ng/dL) is common in patients with cardiovascular disease.
1,25(OH) 2 D exerts its biological activity by binding to and activating the vitamin D receptor (VDR). The liganded VDR heterodimerizes with the retinoid X receptor, or occasionally the retinoic acid receptor, to form the regulatory complex that has been shown to control the expression of as much as 3% of the transcribed genome in target cells. 3 Vitamin D insufficiency (circulating 25(OH)D levels <30 ng/dL) is endemic in the human population with more than a billion people affected worldwide. 1 Epidemiological data indicate that vitamin D deficiency (circulating 25(OH)D levels <20 ng/dL) is common in patients with cardiovascular disease. 1 Reduced plasma 25(OH)D levels are associated with increased risk of hypertension, 4, 5 ischemic heart disease, myocardial infarction, and early mortality. 6 In selected interventional studies, investigators have shown that vitamin D treatment improves endothelial function, [7] [8] [9] lowers blood pressure, 10 and reverses cardiac hypertrophy 11, 12 in humans. These clinical data support the notion that vitamin D deficiency is a risk factor for the development of cardiovascular disease and that restoration of vitamin D levels may mitigate this risk.
Until recently, studies of 1,25(OH) 2 D action were largely confined to the intestinal mucosa and bone where its calcitropic properties have been shown to be critical in supporting skeletal mineralization. More recently, it has become apparent that 1,25(OH) 2 D targets multiple organ systems, modulating functions ranging from epidermal development to immune response to cardiovascular function. VDR and the synthetic machinery for production of 1,25(OH) 2 D are present in multiple cell types throughout the heart and vasculature. [13] [14] [15] We reported previously that the liganded VDR possesses antihypertrophic activity in the heart. 9, 13 The expression of the VDR in cardiac myocytes and fibroblasts is upregulated following exposure to hypertrophic stimuli in vitro and in hypertrophied hearts in vivo. 13 In the vasculature, vitamin D has been shown to control vascular smooth muscle and endothelial cell proliferation. 15, 16 Several, although not all, 17 animal studies suggest that vitamin D promotes blood vessel relaxation and reduces contractile responses to vasoconstrictors in animals with cardiovascular dysfunction. 18, 19 The identity of the vascular cells targeted by vitamin D in these studies remains undefined. Endothelial dysfunction is seen in a variety of conditions that adversely impact the cardiovascular system, including hypertension, diabetes mellitus, hypercholesterolemia, and chronic renal failure, 20 conditions that are also known to be associated with vitamin D deficiency. These associations suggested the possibility of a link between endothelial dysfunction and impaired signaling through the liganded VDR.
In an effort to address this issue in a directed fashion, we have generated a mouse with selective deletion of the VDR gene in endothelial cells. We show that these mice demonstrate impaired endothelium-dependent vasorelaxation and an augmented blood pressure response to the administration of angiotensin II (AngII). Collectively, the data suggest that VDR ligands exert an endothelium-dependent, palliative effect on the vascular tree that is likely to prove important in the maintenance of cardiovascular homeostasis.
Methods
A full description of Materials and Methods is available in the onlineonly Data Supplement.
Endothelial Cell-Specific VDR Knockout Mice
Generation and characterization of a mouse with a targeted (loxPbordered) VDR gene allele (VDR L/L ) has been reported previously. 21 Endothelial cell-specific VDR gene knockout mice in the C57B6 mouse strain were generated by mating VDR L/L female mice with male mice expressing the Cre transgene under the control of Tie-2 gene promoter, 22 which is selectively expressed in the endothelial cell. All experiments were performed in mice at 12 to 24 weeks of age. All animal-related experimental protocols were approved by the Institutional Animal Care and Use Committee at University of California, San Francisco.
Results

Presence of VDR in Endothelial Cells
VDR gene expression has been demonstrated previously using immunohistochemical staining in venular and capillary endothelial cells of human skin biopsies 14 and in endothelial cells lining the rat aorta. 23 We confirmed these findings in human umbilical endothelial cells using both Western blot analysis and immunocytochemistry. In whole-cell lysates of cultured human umbilical endothelial cells, Western analysis, using a rabbit antibody that recognizes the C terminus of VDR protein, detected a band migrating at 55 kDa ( Figure 1A ), consistent with previously reported molecular weights for mammalian VDR proteins. 24 This band was eliminated when antibody was premixed with competing peptide. The same antibody localized VDR protein to the human umbilical endothelial cell nuclei, as shown in Figure 1B .
Specific and Effective Deletion of VDR in Endothelial Cell-Specific VDR Gene Knockout Mouse
To explore the functional role of VDR in endothelial cells, we generated a mouse model with targeted deletion of VDR in endothelial cells using Cre-Lox technology. LoxP sites were placed in intron sequence surrounding exon 4 of the VDR gene with the intention of deleting the coding sequence of the second zinc finger of the VDR ( Figure 1C ). Successful elimination of VDR expression in the mouse cardiac myocyte using the same loxP-bordered allele has been reported previously. 21 We used the Tie-2 promoter-driven Cre transgene 22 to promote ) and VDR ECKO mice. VDR mRNA levels in endothelial cells were reduced by 87% in VDR ECKO mice, whereas VDR expression levels in the nonendothelial cell population were unchanged ( Figure 1E ). Compared with the endothelial cells isolated from control mice, VDR protein expression in endothelial cells from VDR ECKO mice was significantly reduced ( Figure 1F ). As predicted, deletion of VDR in endothelial cells did not affect plasma calcium or phosphorus levels ( Figure S1 in the online-only Data Supplement), indicating that there was no perturbation of systemic mineral metabolism.
Impaired Vasodilation and Reduced Endothelial NO Synthase Expression in Aorta From
VDR ECKO Mouse
Previous reports have linked vitamin D deficiency to impaired endothelial function. 25 We investigated the role of endothelial VDR in supporting endothelial function by examining endothelium-dependent vasorelaxation in an ex vivo model. We compared the vasorelaxant response to acetylcholine in isolated aortae taken from control versus VDR ECKO mice. Figure 2A shows the real-time tracing of aortic tension from control versus VDR ECKO mice. Aortae from both groups were challenged with phenylephrine to generate half-maximal, phenylephrine-induced contraction. Increasing concentrations of acetylcholine were then added to the tissue bath to induce endothelium-dependent relaxation. VDR ECKO mouse aortae demonstrated impaired vasorelaxation compared with control aortae ( Figure 2B ). The relaxation to a maximal concentration of sodium nitroprusside (NO donor, 10 −5 mol/L), an endothelium-independent vasodilator, was not affected by VDR deletion in endothelial cells (Figure 2A) . Similarly, there was no difference in the aortic contraction to phenylephrine in VDR ECKO versus control mice ( Figure 2C ). Collectively, these results demonstrate that endothelial cell-specific deletion of the VDR gene interferes selectively with endotheliumdependent vasorelaxation in mouse aorta.
Acetylcholine-induced relaxations were completely blocked by the endothelial NO synthase (eNOS) inhibitor (N G -nitrol-arginine) in both groups ( Figure 2B ), confirming the fact that NO is the principal mediator of acetylcholine-induced relaxation in mouse aorta. 26 By inference, this suggests that the different vasorelaxant responses that we observed between control and VDR ECKO mice could reflect differences in eNOS expression and activity. As shown in Figure 3A , we found that eNOS mRNA levels were reduced to 62% of those found in control aortae. We found a similar reduction in eNOS protein levels (≈37%) in aortae from VDR ECKO versus control mice ( Figure 3B ). The levels of phospho-vasodilator-stimulated phosphoprotein, a cGMP-sensitive marker of NO activity 27 ( Figure 3C ), were also reduced. These results support the notion that VDR deletion in endothelial cells results in impaired NO signaling. Endothelin-1, a peptide produced predominantly in endothelial cells, is a powerful vasoconstrictor and mitogen that stimulates fibrogenesis. 28 A vitamin D analog has been shown to repress high matrix stiffness-induced endothelin-1 gene transcription. 29 However, we found no change in preproendothelin-1 mRNA expression in aortae from VDR ECKO versus control mice (data not shown). Because reactive oxygen species, such as superoxide, have been shown to impair endothelial function in several systems, [30] [31] [32] we assessed superoxide levels by dihydroethidium staining on frozen cross sections of aortae from control and VDR ECKO mice at 12 weeks of age. We found a significantly higher level of superoxide in the endothelium from VDR ECKO mice compared with that in the control mice, and this difference extended to the entire vascular wall ( Figure S2 ).
It is important to note that Tie-2 Cre expression has also been reported in myeloid cells. 33 Because macrophages from the myeloid lineage are known to contain VDR and might contribute to the phenotypes we are seeing, we sought to determine whether macrophage number was altered in the VDR ECKO aortae at baseline. To address this, we analyzed aortic cell suspensions for the presence of CD11b + and F4:80 + cells (CD11b is a marker for the myeloid linage and F4:80 for macrophage) by fluorescence-activated cell sorter analysis. Isolated aortic cells were stained with CD45 antibody to identify leukocytes in the preparation. There was no significant difference in CD45 + cell number in the control versus VDR ECKO samples ( Figure S3 ). Macrophage number, normalized for live cells (Figure S3 ), or the number of CD45 + cells did not differ significantly in VDR L/L versus VDR ECKO aortic suspensions. If anything there appeared to be a slight, albeit nonsignificant, trend toward a smaller number of macrophages in the VDR ECKO aortae. Macrophage number was consistent with what has previously been reported in aortic cell suspensions. 34 Our data suggest that the impaired vasorelaxant activity seen in VDR ECKO mice results from VDR deletion in endothelial cells.
Blood Pressure and Cardiac Response to AngII Infusion Is Increased in Mice Deficient in Endothelial VDR
At 24 weeks of age, VDR ECKO mice had similar blood pressure and heart weight/body weight ratio compared with control mice (Figure S4 ). Cross-sectional hematoxylin and eosin staining of aorta and carotid artery showed normal blood vessel morphology in the VDR ECKO mouse ( Figure S4 ). Collectively, these data suggest that, at baseline, the cardiovascular phenotype of the VDR ECKO mice is not appreciably different from the controls.
To evaluate the phenotype of the VDR ECKO mouse under the challenge of cardiovascular stress, we subjected 12-to 14-week-old VDR ECKO and control mice to 2 weeks of AngII infusion. We used a low dose of AngII (500 ng/kg/min) to induce a mild increase in blood pressure with minimal cardiac hypertrophy. Blood pressures were measured using the tail cuff method 21 before, 1 week, and 2 weeks after initiation of vehicle or AngII infusion. Blood pressures, before osmotic minipump implantation, were comparable at 12 to 14 weeks of age in control versus VDR ECKO mice. After 1 week, mice receiving AngII had minimal-to-moderate increases in blood pressure, as expected ( Figure 4) Figure 5 ). In addition, AngII treatment resulted in increased vascular fibrosis, as demonstrated by Masson trichrome staining of aortic cross sections ( Figure 5 ). However, there were no differences between AngII-treated VDR L/L controls and VDR ECKO mice in either vessel wall thickness or fibrosis.
The effects of AngII on the heart were evaluated after the 2 weeks of infusion. Figure 6A shows hematoxylin and eosin staining of cardiac sections from the 4 groups of animals. Gravimetric analysis showed similar increases in heart weight/body weight ratio in control and VDR ECKO evaluated using a computerized automated program (http:// www2.le.ac.uk/colleges/medbiopsych/facilities-and-services/ cbs/lite/aif/software-1/imagej-macros). Similar to the results obtained for the heart weight/body weight ratio, increases in myocyte size were comparable in control versus VDR ECKO mice after AngII infusion ( Figure 6C and 6D) . However, when we measured more sensitive markers of cardiac hypertrophy (ie, the expression of fetal genes in left ventricular myocardium), we found that AngII-induced type-A natriuretic peptide and type-B natriuretic peptide gene expression were increased to a higher level in hearts from VDR ECKO mice compared with controls ( Figure 6E and 6F) .
AngII infusion induced a mild degree of cardiac fibrosis in both control and VDR ECKO mice as demonstrated by Masson trichrome staining of cardiac sections ( Figure 7A ). Gene expression analysis showed that collagen 1a1 and collagen 3a1 mRNA increased with AngII infusion, as expected 35 ( Figure 7B) . Additionally, as noted with the hypertrophic marker genes above, collagen 3a1 was induced to a greater extent in hearts from VDR ECKO mice.
Discussion
The present study provides the first evidence of a direct protective role for the endothelial VDR in regulating vascular tone. Our results show that the deletion of VDR in endothelial cells leads to endothelial dysfunction (demonstrated by impaired blood vessel relaxation) and sensitization of mice to the hypertensive effects of AngII infusion. Given the acknowledged importance of endothelial function to cardiovascular homeostasis, the protective activity of VDR in vascular endothelium may account for at least some of the reported beneficial effects attributed to vitamin D in preventing or reversing cardiovascular disease. 36, 37 Several epidemiological studies have demonstrated that individuals with low plasma concentrations of 25(OH)D, the best measure of vitamin D status in humans, are at higher risk for all-cause as well as cardiovascular mortality, 38,39 myocardial infarction, 40 and hypertension. 4, 5 However, these relationships remain controversial, 41 and interventional studies have, by and large, failed to demonstrate major effects of vitamin D on reversing cardiovascular disease outcomes, 42 suggesting that this is an area worthy of further investigation.
One potential target for vitamin D in the cardiovascular system is the endothelial cell. Endothelial cells have been shown to express VDR as well as the ligand-generating 1α-hydroxylase, 14 implying that they possess the capacity for orchestrating local vitamin D-dependent regulatory activity that is confined to the vascular wall. Experimental animal studies support a role for vitamin D in regulating endothelial function. Expression of eNOS was shown to be reduced by 50% in aortic tissue taken from VDR gene knockout (VDR −/− , global VDR knockout) versus wild-type mice. 43 Noteworthy, the authors in that study attributed this reduction to hypocalcemia in the VDR −/− mouse. In our study, VDR ECKO mice were normocalcemic ( Figure S1 ). In another study, advanced glycation end products reduced eNOS gene expression and enzymatic activity. These were restored after treatment with 1,25(OH) 2 D. 44 VDR activators (eg, paricalcitol) have also been shown to mitigate endothelial dysfunction in animals with renal insufficiency. In rats with 5/6 nephrectomy, VDR gene expression was found to be reduced in the endothelium but not in the smooth muscle layer of the vascular wall. This endothelial-specific VDR deficiency was restored after vitamin D analog treatment. 45 Two weeks of paricalcitol treatment dose dependently improved acetylcholine-induced (endothelium-dependent) relaxation in blood vessels from 5/6 nephrectomized rats. 25 In addition, the improved relaxation was abolished by an NO synthase inhibitor suggesting that paricalcitol affected endothelial function by increasing NO production, 25 a finding that complements those reported here. Several clinical studies have demonstrated an inverse correlation between plasma 25(OH)D levels and endothelial function, assessed by flow-mediated vasodilation, in humans. Tarcin et al 46 showed that 25(OH)D deficiency was associated with endothelial dysfunction, and vitamin D replacement was found to be effective in reversing this dysfunction. Jablonski et al 47 found that endothelium-dependent brachial artery flowmediated dilation was lower in vitamin D-insufficient and vitamin D-deficient versus vitamin D-sufficient individuals, whereas endothelium-independent brachial artery dilation did not differ between the groups. Of note, they found an increase in inflammation-linked markers in vitamin D-deficient versus -sufficient subjects and a reduction in both VDR and 1α-hydroxylase expression. They speculated that reduced VDR and local 1,25(OH) 2 D synthesis might account for the link between vitamin D insufficiency and endothelial dysfunction. Harris et al 8 showed that 16 weeks of vitamin D supplementation (60 000 IU monthly) led to significant improvement in flow-mediated dilation in overweight black adults. In view of the well-established link between endothelial dysfunction and adverse cardiovascular events, 20 one could speculate that the increased risk of cardiovascular events and mortality noted above 1 is, at least in part, a reflection of the impaired endothelial function that accompanies inadequate vitamin D activity.
Natriuretic peptides, especially type-B natriuretic peptide, have been considered as diagnostic markers for asymptomatic and symptomatic cardiac dysfunction as well as prognostic markers in patients with heart failure. 48, 49 A recent study showed that even modest elevations in type-B natriuretic peptide in asymptomatic hypertensive patients can be linked to subclinical cardiac remodeling, inflammation, and extracellular matrix changes. 50 Increases in both type-A natriuretic peptide and type-B natriuretic peptide gene expression were amplified in the hearts from VDR ECKO mice after AngII infusion, implying a reduction in the threshold for development of AngII-dependent cardiac pathology. What remains unclear is whether this phenotype (ie, increased expression of natriuretic peptide genes) is a direct result of dysfunctional cardiac endothelial cells, which support cardiac myocyte and fibroblast function, 51, 52 or whether this is an indirect phenomenon resulting from the modestly elevated blood pressures seen in VDR ECKO mice. 
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The casual role of superoxide in contributing to endothelial dysfunction has been studied for more than a decade. [30] [31] [32] Vitamin D deficiency has been linked to increased oxidative stress in previous studies, 53 whereas vitamin D supplementation has been shown to reverse this process in a variety of tissues, including the vasculature. [3] [4] [5] 54 The antioxidant effect of vitamin D was shown to be mediated by the mitogen-activated protein kinase/extracellular signal-regulated kinases/sirtuin-1 axis in endothelial cells. 55 Chronic treatment of the spontaneously hypertensive rat with calcitriol normalized elevations in reactive oxygen species and expression of angiotensin II receptor type 1 and nicotinamide adenine dinucleotide phosphateoxidase subunits in the vasculature. 55 More recently, calcitriol treatment of renal arteries from hypertensive patients, in vitro, has been shown to improve endothelial function and reduce oxidative stress by reducing angiotensin II receptor type 1 and nicotinamide adenine dinucleotide phosphate-oxidase subunits and increasing superoxide dismutase 1, and superoxide dismutase 2 expression. 54 Our data are consistent with these previous findings and demonstrate the important role of VDR in supporting endothelial function more directly in an in vivo model.
As noted above, Tie2-Cre has been shown to be expressed in cells of the myeloid lineage (eg, macrophage), raising the possibility that deletion of the VDR in these cells could contribute to the phenotype observed here. We have examined both aortic sections (immunocytochemistry) and dispersed aortic cells (fluorescence-activated cell sorter) for the presence of immune cells, including cells of the myeloid lineage, and found no difference between the VDR ECKO and control mice. This suggests that the observed effects on vasorelaxant activity and NOS gene expression and activity result from deletion of the VDR gene in the endothelial cell. Although it would seem likely that this would have an effect on blood pressure as well, given the complexity of blood pressure regulation in vivo and the known proinflammatory effects of AngII in the cardiovascular system, 56 it remains possible that some portion of the effects of Tie2-Cre-generated VDR deletion could result from coincident reduction of liganded VDR activity in myeloid cells.
Perspectives
The fact that VDR is expressed in many, if not most, cells of the cardiovascular system [13] [14] [15] makes it difficult to dissect out the mechanism(s) of vitamin D's cardiovascular effects using subjects with vitamin D deficiency or whole animal VDR deletion, because many confounding factors (ie, changes in parathyroid hormone levels or calcium homeostasis) could potentially contribute to the phenotype. Using a mouse model with selective elimination of VDR in endothelial cells, we have provided direct evidence that vitamin D regulates endotheliumdependent blood vessel relaxation and arterial blood pressure, possibly by modulating eNOS gene expression. Our data add another piece of evidence supporting the hypothesis that vitamin D exerts palliative effects in the cardiovascular system and imply that vitamin D or its less-calcemic analogs may be useful in the prevention and treatment of cardiovascular and metabolic diseases that are associated with endothelial dysfunction. 
DATA SUPPLEMENT ELIMINATION OF VITAMIN D RECEPTOR IN VASCULAR ENDOTHELIAL CELLS ALTERS VASCULAR FUNCTION
Methods
AngII Infusion and Blood Pressure Measurement
Mice were anesthetized with 2.5% isoflurane. Alzet micro-osmotic pumps (Model 1002, DURECT Corporation, Cupertino, CA) with a release rate of 0.25ul/hour were implanted subcutaneously between the scapulae of the mouse to deliver saline or AngII (500 ng kg
) continuously for 14 days. Mouse blood pressures were measured using a conventional tail-cuff method. Briefly, mice were trained on the Hatteras Instruments SC1000 Blood Pressure Analysis System for 4 days before pump implantation. Ten consecutive measurements on the day before, day 7 and the last day of infusion were averaged to calculate systolic and diastolic blood pressure. Mean arterial blood pressure was calculated as 2/3 diastolic pressure plus 1/3 systolic blood pressure.
Mouse Endothelial Cell Isolation and Human Umbilical Vein Endothelial Cell (HUVEC) Culture
Vascular endothelial cells were isolated from hearts of 12 week old mice. Left ventricle was removed, cut transversely in two halves and rinsed with cold Hank's Balanced Salt Solution. Single cell suspensions were obtained utilizing a combination of enzymatic dissociation with collagenase II (600 U/ml) and mechanical force with the GentleMACS HUVECs were purchased at passage 3 from ScienCell Research Laboratories. HUVECs were cultured and expanded in Endothelial Cell Medium-complete. At passages 4-7, HUVECs were collected and used to measure VDR protein expression by Western blot analysis and immunocytochemistry.
Isometric Contractions/Relaxations of Mouse Aorta
Mouse aorta strips were mounted in tissue baths for isometric tension recordings using Grass transducers and a PowerLab Data Acquisitions system (Colorado Springs, CO, USA). Aortic strips were placed under optimal resting tension (250 mg) and equilibrated in a tissue bath for 1 hour in aerated (95% O 2 /5% CO 2 ) physiological salt solution M) was used to assess blood vessel viability. To compare contractile function of mouse aorta, concentration-response curves for PE were generated in a cumulative manner. Tissues were then washed repeatedly until tone returned to baseline. To examine the status of the arterial endothelium, tissues were contracted with a half-maximal concentration of PE (determined previously; 10 M) to determine the ability of vessels to relax to an NO stimulus. In some experiments, vehicle or the nitric oxide synthase inhibitor N(G)-nitro-L-arginine (L-NNA) (100 M) was added prior to the addition of PE to contract tissues so that agonist-induced relaxation could be measured.
Quantitative PCR Superoxide analysis in aorta section
Dihydroethidium (DHE) fluorescent analysis was performed on frozen mouse aorta sections (5 μm) incubated with DHE (Sigma, 10 μM) for 10 minutes at 37 °C, and washed with phosphatebuffered saline (PBS). Images were acquired using a confocal laser scanning microscope (Leica TCS SP5) with same exposure time for all aortic sections. Confocal images were analyzed by Image J. DHE fluorescence density was normalized to auto-fluorescence acquired with the default setting for Alexa 488 on Leica TCS SP5 from the same image.
Flow Cytometric Analysis of Aorta and Spleen Cell Suspensions
Aortic cell suspensions were prepared and analyzed according to the procedure of Butcher et al. 2 . Briefly, the vasculature was cleared with PBS containing 2% heparin to remove the blood from the aorta. The aorta was then excised and the adherent adipose tissue and para-aortic lymph nodes were dissected away leaving the aorta and adventia intact. The aorta was digested in PBS containing 125 U/ml Collagenase type XI, 60 U/ml Hyaluronidase type 1-s, 60 U/ml DNase I, and 450 U/ml Collagenase type I for 1 hour at 37 ºC (all enzymes from Sigma Aldrich, St Louis , MO). A single cell suspension was obtained by passing the tissue through a 70 m mesh filter. The spleen was removed and placed in DMEM + 2% fetal calf serum. A single cell suspension was obtained after passing through subsequent 70 m and 40 m mesh filters. The suspension was treated with ACK buffer (Lonza, Walkerville, MD) to remove red blood cells. The aorta and spleen cells were re-suspended in PBS containing 1% BSA. Cells (aorta: 7.5 x10 4 and spleen 5x10 5 ) were treated with Fc block and stained with the following conjugated antibodies: CD11b-phycoerythrin (PE) (eBiosciecne cat # 12-0112), F4:80-fluorescein isothiocyanate (FITC) (eBioscience cat # 11-4801) and CD45-allophycocyanin (APC) (eBioscience cat # 9017-9459). Dead cells were analyzed by staining with LIVE/DEAD Fixable Violet kit (Invitrogen) according to the manufacturer's instructions. Acquisition was performed on a BD FACS Calibur flow cytometer, and the data analyzed using FlowJo software.
Statistical Analysis
Data were analyzed using ANOVA, with Newman-Keuls posthoc test, or Students t-test, where appropriate. Results are presented as mean ± standard error of the mean (SEM). 
